ExeVir Bio contracte un prêt d’amorçage-investissement de 25 millions d’euros auprès de la Banque européenne d’investissement
January 09, 2023 02:00 ET
|
ExeVir Bio
Financer le développement scientifique de traitements innovants contre le COVID-19 basés sur des nanocorps, visant à protéger des personnes immunodéprimées à haut risque L’entreprise développe des...
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
January 09, 2023 02:00 ET
|
ExeVir Bio
Financing to advance the scientific development of innovative COVID-19 nanobody treatments focused on protecting high-risk immunocompromised individuals Company developing highly potent antibodies...
Axiom Real-Time Metrics Attending J.P. Morgan Healthcare and Biotech Showcase Conferences
January 08, 2023 22:06 ET
|
Axiom Real-Time Metrics Inc
TORONTO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations,...
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
January 08, 2023 18:00 ET
|
Phathom Pharmaceuticals
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data...
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
January 06, 2023 14:50 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
January 06, 2023 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced...
Insilico Medicine launches 6th generation Intelligent Robotics Lab to further accelerate its AI-driven drug discovery
January 05, 2023 09:00 ET
|
InSilico Medicine
New York, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life...
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
January 05, 2023 08:30 ET
|
Vaxcyte, Inc.
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest...
Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies
January 05, 2023 07:30 ET
|
Frontier Medicines
FMC-376 directly, rapidly, and completely blocks both active and inactive forms of KRASG12C to overcome non-response and resistance seen with prior generation KRASG12C inhibitors The company has...
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
January 05, 2023 07:30 ET
|
Surface Oncology, Inc.
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical...